Login / Signup

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.

Bo ZhangJinbo YueXuetao ShiKai CuiLei LiChengsheng ZhangPengfei SunJingtao ZhongZhongchao LiLei Zhao
Published in: BMJ open (2022)
NCT05185531.
Keyphrases
  • locally advanced
  • rectal cancer
  • randomized controlled trial
  • early stage
  • radiation therapy
  • squamous cell carcinoma
  • lymph node
  • radiation induced
  • liver metastases